Board changes - Replacement

AI SummaryClose X

CelLBxHealth PLC has amended a previous announcement regarding board changes, adding that Non-Executive Director Klaas de Boer holds 2,002,319 ordinary shares, representing approximately 0.18% of the company's issued share capital. This amendment follows the appointments of Peter Collins as Chief Executive Officer and Klaas de Boer, Kim Oreskovic, and Benjamin Hart as Non-Executive Directors, while Joseph Eid steps down from the board. The company, a leader in circulating tumour cell intelligence, aims to leverage the expertise of its new board members to focus on strategic opportunities and deliver long-term shareholder value.

Disclaimer*

UK 100

Latest directors dealings